Treatment

“Less is more” in medication-overuse headache

6668 2484 Peter Stevenson, PhD

Monitoring, recognition and effective patient education are cornerstones in the diagnosis and prevention of medication-overuse headache (MOH), delegates heard at the 5th Annual Congress of the European Academy of Neurology…

read more

Treating nature with NURTURE: Interim results of nusinersen for SMA

3473 2300 Mea Holm, PhD

Promising results for a disease-modifying treatment for spinal muscular atrophy (SMA) were presented at the 5th Annual Congress of the European Academy of Neurology (EAN) in Oslo, Norway, last week.…

read more

Natalizumab treatment associated with reduction of gliotic biomarkers in white matter

3067 2300 Michael Furrer, PhD

New data on the effect of natalizumab treatment on neuronal and membrane integrity in lesional white matter were presented at the recent 5th Annual Congress of the European Academy of…

read more

8-year follow-up data of alemtuzumab presented

1920 1280 Michael Furrer, PhD

An update of the long-term efficacy and safety data of alemtuzumab in patients with relapsing-remitting MS was presented at the 5th Annual Congress of the European Academy of Neurology (EAN)…

read more
man speaking

Machine-learning algorithm predicts psychosis from speech

3150 2100 Peter Stevenson, PhD

Algorithms designed to find hidden clues within everyday language can predict those at risk of developing psychosis, a new study reports. Using machine learning, researchers from the Department of Psychology…

read more

FDA issues warnings on illegal Alzheimer’s drugs

2880 1920 Peter Stevenson, PhD

On 11 February 2019, the United States Food and Drug Administration (FDA) issued warnings to 17 companies that illegally sold more than 50 products claiming to prevent, treat or cure…

read more

Stem-cell therapy puts the brakes on MS

2850 1900 Peter Stevenson, PhD

New data reveal the power of stem-cell transplantation in slowing or even halting disease progression in patients with RRMS, thereby reinvigorating further exploration of cellular treatments in MS. The findings…

read more

Cognitive impairment in MS

2048 1153 Mea Holm, PhD

Up to 70% of MS patients suffer from cognitive decline, which often has a profound impact on an individual’s quality of life. It is little surprise that MS researchers are…

read more

Results from the MS-SMART trial unveiled

3971 2975 Mea Holm, PhD

Secondary progressive multiple sclerosis (SPMS) is known to be extremely difficult to treat; there are no effective therapies for halting or reversing disability progression in the late disease phase. In…

read more

MS treatment strategy: Hitting hard and early, or minimising risks through stepwise escalation?

1969 1525 Mea Holm, PhD

With more than a dozen approved treatment options for relapsing-remitting multiple sclerosis (RRMS), treatment decision making is an increasingly complex task for neurologists. At ECTRIMS 2018, the topic on which…

read more
Brainwork is supported by unrestricted grants from: